Picture of Takeda Pharmaceutical Co logo

TAK Takeda Pharmaceutical Co News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapSuper Stock

REG - Nomura Holdings, Inc Takeda Pharma.Co.Ltd - Form 8 (DD) - Takeda Pharmaceutical Company Ltd





 




RNS Number : 7827H
Nomura Holdings, Inc
19 November 2018
 

FORM 8.4 (DD)

 

PUBLIC DEALING DISCL

OSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)

Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION

 

(a) Full name of discloser:

Nomura Holdings Inc.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

NA

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

     Use a separate form for each offeror/offeree

Takeda Pharmaceutical Company Limited

(d) Status of person making the disclosure:

     e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)

Joint Financial Advisor to Takeda Pharmaceutical Company Limited

(e) Date dealing undertaken:

16 November 2018

(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

     If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A

If YES, specify which: NO

 

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose      in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.                          

 

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

 

Class of relevant security: JP3463000004

                                                                                                                                                                                                              

Ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

351,707

0.045

810,701

0.103

(2) Cash-settled derivatives:

 

808,470

0.103

350,000

0.045

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.000

130,800

0.017

 

     TOTAL:

1,160,177

0.148

1,291,501

0.165

 

All interests and all short positions should be disclosed.

           

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b)        Rights to subscribe for new securities (including directors' and other employee options)

                                   

Class of relevant security in relation to which subscription right exists:

Nil

Details, including nature of the rights concerned and relevant percentages:

Nil

 

3.         DEALINGS BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)        Purchases and sales

 

(i)         Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

 

 

 

(ii)        Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary

Purchase

661,300

4322.8249

4299.3942

Ordinary

Purchase

45,200

4357.0000

4289.5000

Ordinary

Sale

533,700

4605.0000

4300.9059

Ordinary

Sale

54,500

4315.0000

4291.0000

 

 (b)       Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Ordinary shares

Swap

Long

1,600

4301.2500

Ordinary shares

Swap

Long

14,000

4310.5036

Ordinary shares

Swap

Long

5,700

4310.5158

Ordinary shares

Swap

Long

62,700

4311.2179

Ordinary shares

Swap

Long

219,100

4311.2186

Ordinary shares

Swap

Long

3,300

4316.3636

Ordinary shares

Swap

Long

76,800

4316.7035

Ordinary shares

Swap

Long

136,700

4316.9568

Ordinary shares

Swap

Long

200

4322.0000

Ordinary shares

Swap

Long

13,600

4605.0000

Ordinary shares

Swap

Short

1,800

4299.2222

Ordinary shares

Swap

Short

7,900

4304.4342

Ordinary shares

Swap

Short

12,400

4304.4943

Ordinary shares

Swap

Short

16,300

4305.2730

Ordinary shares

Swap

Short

18,200

4308.9082

Ordinary shares

Swap

Short

148,000

4309.0289

Ordinary shares

Swap

Short

238,100

4311.1613

Ordinary shares

Swap

Short

32,100

4313.1665

Ordinary shares

Swap

Short

132,300

4315.3054

Ordinary shares

Swap

Short

100

4319.0000

Ordinary shares

Swap

Short

1,500

4321.9333

Ordinary shares

Swap

Short

52,600

4322.6520

                                                                                                                       

(c)        Stock-settled derivative transactions (including options)

 

(i)         Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

                           

 

 (ii)       Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d)        Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

 

4.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:

Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"

 

NA

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NA

 

 

(c)        Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

YES

Supplemental Form 8 (SBL)

YES

 

 

Date of disclosure:

19 November 2018

Contact name:

Kyere Tabiri

Telephone number:

020 7102 1267

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

http://www.rns-pdf.londonstockexchange.com/rns/7827H_1-2018-11-19.pdf

 

http://www.rns-pdf.londonstockexchange.com/rns/7827H_2-2018-11-19.pdf


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DCCKMMMMMLKGRZM

Recent news on Takeda Pharmaceutical Co

See all news